Recomendaciones para una prescripción segura de antiinflamatorios no esteroideos: documento de consenso elaborado por expertos nominados por 3 sociedades científicas (SER-SEC-AEG)

European Medicines Agency. European Medicines Agency review concludes positive benefit-risk balance for non-selective NSAIDs London: EMA; 2006 [updated 3 May 2013; consultado 19 Dic 2005]. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/12/news_detail_000752.jsp&mid=WC0b01ac058004d5c1 Lanas, 2003, Estrategia clínica para la prevención de los efectos adversos sobre el tracto digestivo de los antiinflamatorios no esteroideos, Rev Esp Reumatol, 30, 393 Lanas, 2003, Clinical strategy to prevent the gastrointestinal adverse effects of nonsteroidal anti-inflammatory agents, Gastroenterol Hepatol, 26, 485, 10.1157/13051932 Bori Segura, 2009, Appropriate use of non-steroidal anti-inflammatory drugs in rheumatology: Guidelines from the Spanish Society of Rheumatology and the Mexican College of Rheumatology, Reumatol Clin, 5, 3, 10.1016/S1699-258X(09)70197-4 Scottish Intercollegiate Guidelines Network. SIGN Scottish Intercollegiate Guidelines Network Edinburgh: Scottish Intercollegiate Guidelines Network; 1993 [consultado 22 Jul 2013]. Disponible en: http://www.sign.ac.uk/index.html Bjordal, 2004, Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: Meta-analysis of randomised placebo controlled trials, BMJ, 329, 1317, 10.1136/bmj.38273.626655.63 Chen, 2008, Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: A systematic review and economic evaluation, Health Technol Assess, 12, 1, 10.3310/hta12110 U.S. Food and Drug Administration. Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Silver Spring: FDA; 2007 [actualizado 24 May 2013; consultado 22 Jul 2013]. Disponible en: http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089162.pdf Hunt, 2007, Approach to managing musculoskeletal pain: Acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?, Can Fam Physician, 53, 1177 Schnitzer, 2006, Update on guidelines for the treatment of chronic musculoskeletal pain, Clin Rheumatol, 25, S22, 10.1007/s10067-006-0203-8 Kean, 2008, Management of chronic musculoskeletal pain in the elderly: Opinions on oral medication use, Inflammopharmacology, 16, 53, 10.1007/s10787-008-1623-7 Strand, 2011, Treatment of osteoarthritis with continuous versus intermittent celecoxib, J Rheumatol, 38, 2625, 10.3899/jrheum.110636 Luyten, 2007, A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip, Ann Rheum Dis, 66, 99, 10.1136/ard.2006.052308 Gossec, 2012, European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies, Ann Rheum Dis, 71, 4, 10.1136/annrheumdis-2011-200350 Braun, 2011, 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis, Ann Rheum Dis, 70, 896, 10.1136/ard.2011.151027 Escalas, 2010, Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: Results of a meta-analysis, Rheumatology (Oxford), 49, 1317, 10.1093/rheumatology/keq078 Sieper, 2008, Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: Results of a 12-week randomised, double-blind, controlled study, Ann Rheum Dis, 67, 323, 10.1136/ard.2007.075309 Van der Heijde, 2005, Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study, Arthritis Rheum, 52, 1205, 10.1002/art.20985 Van den Berg, 2012, First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: A systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis, Rheumatology (Oxford), 51, 1388, 10.1093/rheumatology/kes066 Haroon, 2011, Continuance of non-steroidal anti-inflammatory drugs may reduce radiographic progression in ankylosing spondylitis patients on biological therapy, Arthritis Rheum, 63, 1303 Wanders, 2005, Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial, Arthritis Rheum, 52, 1756, 10.1002/art.21054 Poddubnyy, 2012, Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort, Ann Rheum Dis, 71, 1616, 10.1136/annrheumdis-2011-201252 Kroon, 2012, Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis, Ann Rheum Dis, 71, 1623, 10.1136/annrheumdis-2012-201370 Benhamou, 2010, Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/COXIB’ treatment effect on C-reactive protein, Rheumatology (Oxford), 49, 536, 10.1093/rheumatology/kep393 Song, 2008, Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs, Arthritis Rheum, 58, 929, 10.1002/art.23275 Ramiro, 2011, Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis), Cochrane Database Syst Rev, 10, CD008886 Garner, 2005, Rofecoxib for rheumatoid arthritis, Cochrane Database Syst Rev, 1, CD003685 Wienecke, 2004, Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis, Cochrane Database Syst Rev, 1, CD003789 Pincus, 2004, Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): Two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis, Ann Rheum Dis, 63, 931, 10.1136/ard.2003.020313 Rabenda, 2005, A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs, Ann Rheum Dis, 64, 688, 10.1136/ard.2004.026658 Schussel, 2006, Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals, Pharmazie, 61, 878 Barozzi, 2008, Cyclooxygenase-2 inhibitors and paracetamol use in Queensland and in the whole of Australia, BMC Health Serv Res, 8, 196, 10.1186/1472-6963-8-196 Conroy, 2003, Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project, Eur Heart J, 24, 987, 10.1016/S0195-668X(03)00114-3 Reiner, 2011, ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J, 32, 1769, 10.1093/eurheartj/ehr158 Perk, 2012, Eur Heart J, 33, 1635, 10.1093/eurheartj/ehs092 Gil-Guillen, 2007, Agreement between REGICOR and SCORE scales in identifying high cardiovascular risk in the Spanish population, Rev Esp Cardiol, 60, 1042 Ruiz-Villaverde, 2006, Comparison of the Score and Framingham-DORICA models to estimate the cardiovascular risk in a cohort of hypertensive patients from southern Spain, Med Clin (Barc), 127, 314, 10.1016/S0025-7753(06)72242-4 Peters, 2010, EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis, Ann Rheum Dis, 69, 325, 10.1136/ard.2009.113696 Bresalier, 2005, Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N Engl J Med, 352, 1092, 10.1056/NEJMoa050493 Juni, 2004, Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis, Lancet, 364, 2021, 10.1016/S0140-6736(04)17514-4 European Medicines Agency. Questions and answers on the review of non selective non-steroidal anti inflammatory drugs (NSAIDs) and cardiovascular risk London: EMA; 2012 [actualizado 3 May de 2013; consultado 22 Jul 2013]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/10/WC500134095.pdf Varas-Lorenzo, 2011, Stroke risk and NSAIDs: A systematic review of observational studies, Pharmacoepidemiol Drug Saf, 20, 1225, 10.1002/pds.2227 Chen, 2007, Risk of myocardial infarction associated with selective COX-2 inhibitors: Meta-analysis of randomised controlled trials, Pharmacoepidemiol Drug Saf, 16, 762, 10.1002/pds.1409 McGettigan, 2011, Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies, PLoS Med, 8, e1001098, 10.1371/journal.pmed.1001098 Combe, 2009, Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study), Rheumatology (Oxford), 48, 425, 10.1093/rheumatology/kep005 2013, Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials, Lancet, 382, 769, 10.1016/S0140-6736(13)60900-9 Bueno, 2010, Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome, Am J Cardiol, 105, 1102, 10.1016/j.amjcard.2009.12.008 Johnsen, 2001, Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants, Thromb Haemost, 86, 563, 10.1055/s-0037-1616087 Knijff-Dutmer, 2003, Concomitant coumarin-NSAID therapy and risk for bleeding, Ann Pharmacother, 37, 12, 10.1345/aph.1C157 Shorr, 1993, Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease, Arch Intern Med, 153, 1665, 10.1001/archinte.1993.00410140047006 Weil, 2000, Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs, Gut, 46, 27, 10.1136/gut.46.1.27 Holster, 2013, New oral anticoagulants increase risk for gastrointestinal bleeding: A systematic review and meta-analysis, Gastroenterology, 145, 105, 10.1053/j.gastro.2013.02.041 Chan, 1995, Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: Mechanisms, clinical significance, and avoidance, Ann Pharmacother, 29, 1274, 10.1177/106002809502901214 Karim, 2000, Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects, J Clin Pharmacol, 40, 655, 10.1002/j.1552-4604.2000.tb05992.x Knijff-Dutmer, 1999, Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis, Ann Rheum Dis, 58, 257, 10.1136/ard.58.4.257 Van Hecken, 2000, Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers, J Clin Pharmacol, 40, 1109, 10.1177/009127000004001005 Battistella, 2005, Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors, Arch Intern Med, 165, 189, 10.1001/archinte.165.2.189 Cheetham, 2009, Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin, Ann Pharmacother, 43, 1765, 10.1345/aph.1M284 Dentali, 2006, Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial, Ann Pharmacother, 40, 1241, 10.1345/aph.1G733 Antman, 2007, Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association, Circulation, 115, 1634, 10.1161/CIRCULATIONAHA.106.181424 Capone, 2005, Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects, J Am Coll Cardiol, 45, 1295, 10.1016/j.jacc.2005.01.045 Catella-Lawson, 2001, Cyclooxygenase inhibitors and the antiplatelet effects of aspirin, N Engl J Med, 345, 1809, 10.1056/NEJMoa003199 Kimmel, 2003, Giving aspirin and ibuprofen after myocardial infarction, BMJ, 327, 1298, 10.1136/bmj.327.7427.1298 Gengo, 2008, Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: Clinical consequences in stroke prophylaxis, J Clin Pharmacol, 48, 117, 10.1177/0091270007310379 U.S. Food and Drug Administration. Concomitant Use of Ibuprofen and Aspirin: Potential for Attenuation of the Anti-Platelet Effect of Aspirin Silver Spring.: FDA; 2006 [consultado 29 Ene 2007]. Disponible en: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM161282.pdf Anzellotti, 2011, Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: Recommendations to minimize the functional consequences, Arthritis Rheum, 63, 850, 10.1002/art.30175 MacDonald, 2003, Effect of ibuprofen on cardioprotective effect of aspirin, Lancet, 361, 573, 10.1016/S0140-6736(03)12509-3 Curtis, 2003, Aspirin, ibuprofen, and mortality after myocardial infarction: Retrospective cohort study, BMJ, 327, 1322, 10.1136/bmj.327.7427.1322 Schnitzer, 2004, Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial, Lancet, 364, 665, 10.1016/S0140-6736(04)16893-1 Hernandez-Diaz, 2001, Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs, Am J Med, 110, 20S, 10.1016/S0002-9343(00)00682-3 Laine, 2002, Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis, Gastroenterology, 123, 1006, 10.1053/gast.2002.36013 Lanas, 2001, Clinical approach for the patient requiring non-steroid anti-inflammatory agents: Role of COX-2 inhibitors, Gastroenterol Hepatol, 24, 22, 10.1016/S0210-5705(01)70130-6 Gabriel, 1991, Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis, Ann Intern Med, 115, 787, 10.7326/0003-4819-115-10-787 Gutthann, 1997, Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation, Epidemiology, 8, 18, 10.1097/00001648-199701000-00003 Henry, 1993, Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs, Gastroenterology, 105, 1078, 10.1016/0016-5085(93)90952-9 Garcia Rodriguez, 1994, Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs, Lancet, 343, 769, 10.1016/S0140-6736(94)91843-0 Lanas, 1997, Evidence of aspirin use in both upper and lower gastrointestinal perforation, Gastroenterology, 112, 683, 10.1053/gast.1997.v112.pm9041228 Laine, 1999, A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group, Gastroenterology, 117, 776, 10.1016/S0016-5085(99)70334-3 Silverstein, 1995, Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 123, 241, 10.7326/0003-4819-123-4-199508150-00001 Masso Gonzalez, 2010, Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding, Arthritis Rheum, 62, 1592, 10.1002/art.27412 Garcia Rodriguez, 2011, Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications, Circulation, 123, 1108, 10.1161/CIRCULATIONAHA.110.973008 Silverstein, 2000, Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study, JAMA, 284, 1247, 10.1001/jama.284.10.1247 Lanas, 2006, Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations, Gut, 55, 1731, 10.1136/gut.2005.080754 Rahme, 2007, Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: A retrospective cohort study, Aliment Pharmacol Ther, 26, 1387, 10.1111/j.1365-2036.2007.03523.x Rostom, 2007, Gastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane Collaboration systematic review, Clin Gastroenterol Hepatol, 5, 818e1-5, 10.1016/j.cgh.2007.03.011 Rahme, 2007, Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: Does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study, Rheumatology (Oxford), 46, 435, 10.1093/rheumatology/kel428 Loza, 2008, Systematic review: Is there contraindication to the concomitant use of non-sterodial anti-inflammatory drugs and steroids?, Reumatol Clin, 4, 220, 10.1016/S1699-258X(08)75542-6 Loza, 2008, Systematic review on the safety of concomitant use of hypoglycemia-inducing drugs and non-steroidal anti-inflammatory drugs in patients with musculoskeletal pathology, Reumatol Clin, 4, 232, 10.1016/S1699-258X(08)75544-X Hernandez-Diaz, 2000, Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s, Arch Intern Med, 160, 2093, 10.1001/archinte.160.14.2093 Schjerning Olsen, 2011, Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: A nationwide cohort study, Circulation, 123, 2226, 10.1161/CIRCULATIONAHA.110.004671 Boike, 2012, Does concomitant use of paracetamol potentiate the gastroduodenal mucosal injury associated with aspirin? A prospective, randomised, pilot study, Aliment Pharmacol Ther, 36, 391, 10.1111/j.1365-2036.2012.05200.x Wilcox, 2006, Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin, Clin Gastroenterol Hepatol, 4, 1082, 10.1016/j.cgh.2006.04.010 Lanas, 2005, A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use, Am J Gastroenterol, 100, 1685, 10.1111/j.1572-0241.2005.41833.x Curtis, 2012, Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis, Arthritis Care Res (Hoboken), 64, 1819, 10.1002/acr.21764 Ng, 2012, Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction, Am J Gastroenterol, 107, 389, 10.1038/ajg.2011.385 Ng, 2010, Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions, Gastroenterology, 138, 82, 10.1053/j.gastro.2009.09.063 Nishino, 2011, Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers, J Clin Pharmacol, 51, 1079, 10.1177/0091270010376194 Goldstein, 2005, Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: A randomized trial, Am J Gastroenterol, 100, 2650, 10.1111/j.1572-0241.2005.00243.x Yeomans, 1998, A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group, N Engl J Med, 338, 719, 10.1056/NEJM199803123381104 Graham, 2002, Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole, Arch Intern Med, 162, 169, 10.1001/archinte.162.2.169 Hawkey, 1998, Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group, N Engl J Med, 338, 727, 10.1056/NEJM199803123381105 Cryer, 2011, A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials, Ann Med, 43, 594, 10.3109/07853890.2011.625971 Chan, 2010, Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial, Lancet, 376, 173, 10.1016/S0140-6736(10)60673-3 Bombardier, 2000, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group, N Engl J Med, 343, 1520, 10.1056/NEJM200011233432103 Singh, 2006, Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study, Am J Med, 119, 255, 10.1016/j.amjmed.2005.09.054 Goldstein, 2007, Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy, Aliment Pharmacol Ther, 25, 1211, 10.1111/j.1365-2036.2007.03312.x Goldstein, 2005, Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo, Clin Gastroenterol Hepatol, 3, 133, 10.1016/S1542-3565(04)00619-6 Hooper, 2004, The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: Systematic review, BMJ, 329, 948, 10.1136/bmj.38232.680567.EB Goldstein, 2011, Haemoglobin decreases in NSAID users over time: An analysis of two large outcome trials, Aliment Pharmacol Ther, 34, 808, 10.1111/j.1365-2036.2011.04790.x Laine, 2008, Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac, Gastroenterology, 135, 1517, 10.1053/j.gastro.2008.07.067 Sostres, 2011, Should prophylactic low-dose aspirin therapy be continued in peptic ulcer bleeding?, Drugs, 71, 1, 10.2165/11585320-000000000-00000 Sung, 2010, Continuation of low-dose aspirin therapy in peptic ulcer bleeding: A randomized trial, Ann Intern Med, 152, 1, 10.7326/0003-4819-152-1-201001050-00179 Nagahara, 2011, Effect of low dose aspirin on frequency and symptom of GERD, Gastroenterology, 140, S586, 10.1016/S0016-5085(11)62426-8 Casado Arroyo, 2012, Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: Long-term follow-up of a cohort of patients commonly using PPI co-therapy, Heart, 98, 718, 10.1136/heartjnl-2012-301632 Rostom, 2005, Nonsteroidal anti-inflammatory drugs and hepatic toxicity: A systematic review of randomized controlled trials in arthritis patients, Clin Gastroenterol Hepatol, 3, 489, 10.1016/S1542-3565(04)00777-3 Soni, 2009, The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: Pooled analysis of 41 randomized controlled trials, Curr Med Res Opin, 25, 1841, 10.1185/03007990903018279 Bessone, 2010, Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?, World J Gastroenterol, 16, 5651, 10.3748/wjg.v16.i45.5651 Laine, 2009, How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial, Am J Gastroenterol, 104, 356, 10.1038/ajg.2008.149 Ali, 2011, Naproxen-induced liver injury, Hepatobiliary Pancreat Dis Int, 10, 552, 10.1016/S1499-3872(11)60093-3 Nachimuthu, 2001, Acute hepatocellular and cholestatic injury in a patient taking celecoxib, Postgrad Med J, 77, 548, 10.1136/pmj.77.910.548 Jones, 1998, Fulminant hepatic failure due to diclofenac treated successfully by orthotopic liver transplantation, Transplant Proc, 30, 192, 10.1016/S0041-1345(97)01228-1 Selz, 1993, Fatal sub-fulminant hepatitis due to diclofenac, Rev Med Suisse Romande, 113, 985 De Ledinghen, 1999, Anti-inflammatory drugs and variceal bleeding: A case-control study, Gut, 44, 270, 10.1136/gut.44.2.270 Wong, 1993, Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis, Gastroenterology, 104, 869, 10.1016/0016-5085(93)91024-C Boyer, 1979, Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease, Gastroenterology, 77, 215, 10.1016/0016-5085(79)90268-3 Claria, 2005, Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites, Hepatology, 41, 579, 10.1002/hep.20595 Agrawal, 2003, Pharmacokinetics of etoricoxib in patients with hepatic impairment, J Clin Pharmacol, 43, 1136, 10.1177/0091270003257219 Zerbib, 2004, Treatment of NSAIDs related dyspepsia, Gastroenterol Clin Biol, 28, C73, 10.1016/S0399-8320(04)95281-5 Spiegel, 2006, Comparing rates of dyspepsia with COXIB vs NSAID+PPI: A meta-analysis, Am J Med, 119, 448, 10.1016/j.amjmed.2005.11.020 Lai, 2005, Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications, Am J Med, 118, 1271, 10.1016/j.amjmed.2005.04.031 Chan, 2004, Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: Results of a randomized double-blind trial, Gastroenterology, 127, 1038, 10.1053/j.gastro.2004.07.010 Chan, 2002, Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis, N Engl J Med, 347, 2104, 10.1056/NEJMoa021907 Generini, 2002, Therapy of spondylarthropathy in inflammatory bowel disease, Clin Exp Rheumatol, 20, S88 Forrest, 2004, Systematic review: Is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease?, Aliment Pharmacol Ther, 20, 1035, 10.1111/j.1365-2036.2004.02270.x Chan, 2011, Aspirin in the aetiology of Crohn's disease and ulcerative colitis: A European prospective cohort study, Aliment Pharmacol Ther, 34, 649, 10.1111/j.1365-2036.2011.04784.x Bernstein, 2010, A prospective population-based study of triggers of symptomatic flares in IBD, Am J Gastroenterol, 105, 1994, 10.1038/ajg.2010.140 Takeuchi, 2006, Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease, Clin Gastroenterol Hepatol, 4, 196, 10.1016/S1542-3565(05)00980-8 El Miedany, 2006, The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases, Am J Gastroenterol, 101, 311, 10.1111/j.1572-0241.2006.00384.x Sandborn, 2006, Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study, Clin Gastroenterol Hepatol, 4, 203, 10.1016/j.cgh.2005.12.002 Bijlsma, 2010, Patient benefit-risk in arthritis—a rheumatologist's perspective, Rheumatology (Oxford), 49, ii11, 10.1093/rheumatology/keq057 Zhang, 2006, Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: Meta-analysis of randomized trials, JAMA, 296, 1619, 10.1001/jama.296.13.jrv60015 Marks, 2011, Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity, Cochrane Database Syst Rev, 10, CD008952 Alcazar, 2008, SEN-SEMFYC consensus document on chronic kidney disease, Nefrologia, 28, 273 Whelton, 1999, Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications, Am J Med, 106, 13S, 10.1016/S0002-9343(99)00113-8 Moore, 2005, Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: Systematic review and meta-analysis of information from company clinical trial reports, Arthritis Res Ther, 7, R644, 10.1186/ar1704 Pope, 1993, A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure, Arch Intern Med, 153, 477, 10.1001/archinte.1993.00410040045007 Chan, 2009, Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis, J Hypertens, 27, 2332, 10.1097/HJH.0b013e3283310dc9 Aw, 2005, Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure, Arch Intern Med, 165, 490, 10.1001/archinte.165.5.ioi50013 Lanas, 2009, Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications, Gastroenterol Clin North Am, 38, 333, 10.1016/j.gtc.2009.03.007 Graham, 2005, Visible small-intestinal mucosal injury in chronic NSAID users, Clin Gastroenterol Hepatol, 3, 55, 10.1016/S1542-3565(04)00603-2 Maiden, 2007, Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: A cross-sectional capsule enteroscopy study, Clin Gastroenterol Hepatol, 5, 1040, 10.1016/j.cgh.2007.04.031 Cryer, 2013, GI-REASONS: A novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial, Am J Gastroenterol, 108, 392, 10.1038/ajg.2012.467 Maund, 2011, Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: A systematic review, Br J Anaesth, 106, 292, 10.1093/bja/aeq406 Lee, 2007, Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function, Cochrane Database Syst Rev, 2, CD002765 Derry, 2012, Single dose oral celecoxib for acute postoperative pain in adults, Cochrane Database Syst Rev, 3, CD004233 Clarke, 2012, Single dose oral etoricoxib for acute postoperative pain in adults, Cochrane Database Syst Rev, 4, CD004309 2004 Ministerio de Sanidad Servicios Sociales e Igualdad. Enantyum® 50mg/2ml, Solución Inyectable o Concentrado para Solución para Perfusión Madrid: MSSSI; 2009 [consultado 30 Jul 2012]. Disponible en: http://www.msssi.gob.es/profesionales/farmacia/informaMedicamentos/doc/enantyum.doc